Bioprinting is rapidly evolving from an emerging laboratory technology into a transformative clinical platform with the potential to redefine regenerative medicine. This roundtable will bring together key European stakeholders from biofabrication, robotics, clinical translation and advanced manufacturing to discuss how bioprinting can successfully move from research environments into real-world medical practice.
Through complementary perspectives, the discussion will address the major challenges and opportunities facing the field: unmet clinical needs
, in vivo bioprinting, robotic-assisted biofabrication, industrial scalability, regulatory pathways, hospital integration and next-generation regenerative therapies. The session aims to provide a realistic and strategic vision of how the clinical future of bioprinting can be built.
The roundtable would be moderated by Andrea García Lizarribar (TECNALIA), who will guide the discussion around the technological, clinical and industrial pathways required to accelerate the adoption of biofabrication technologies in healthcare.
The proposed panel creates a strong and complementary storyline around the clinical translation of bioprinting technologies:
- Enabling technologies and manufacturing platforms → REGEMAT 3D
Together, the panel balances:
- clinical perspective
- industrial scalability
- enabling technologies
- advanced therapies
- future-oriented innovation
- while maintaining a realistic and high-impact discussion on how bioprinting can successfully transition from research laboratories into clinical practice.
The session offers a unique opportunity to showcase how European innovation ecosystems are shaping the future of clinically applicable biofabrication technologies.
